BIIB · Biogen Inc.
Market Cap
$32.87B
Shares
147.64M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$9.89B
+2.2%
FY2025
Net Income
$1.29B
-20.8%
FY2025
Gross Margin
86.57%
+0.2pp
FY2020
Operating Margin
25.87%
-8pp
FY2021
Diluted EPS
$8.79
-21.4%
FY2025
Operating Cash Flow
$2.2B
-23.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.94B | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.7B | $6.93B | $5.52B | $5.05B | $4.72B | $4.38B | $4.1B | $3.17B | |
| $2.44B | $2.4B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | $857.7M | $545.49M | $466.78M | $400.26M | $382.1M | $401.99M | $335.19M | |
| — | — | — | — | — | — | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | $6.07B | $4.97B | $4.58B | $4.32B | $4B | — | — | |
| — | — | — | — | — | — | 86.57% | 86.4% | 86.5% | 86.72% | 87.08% | 88.48% | 87.93% | 87.63% | 90.11% | 90.76% | 91.51% | 91.27% | — | — | |
| $1.88B | $1.78B | $1.98B | $2.45B | $2.23B | $2.5B | $3.99B | $2.28B | $2.6B | $2.25B | $1.97B | $2.01B | $1.89B | $1.44B | $1.33B | $1.22B | $1.25B | $1.28B | $1.07B | $925.16M | |
| $2.47B | $2.43B | $2.4B | $2.55B | $2.4B | $2.67B | $2.5B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | $1.71B | $1.28B | $1.06B | $1.03B | $911.03M | $925.31M | $776.1M | |
| — | $507.1M | $386.5M | $240.6M | $246.3M | $252M | $255.1M | $274M | $381.2M | $455.3M | $373.4M | $382.6M | $489.8M | $342.9M | $202.2M | $208.57M | $208.93M | $289.81M | $332.75M | $257.5M | |
| $801.1M | $779.9M | $673.2M | $494.8M | $518.4M | $487.7M | $457.2M | $464.7M | $650.5M | $1.08B | $682.7M | $600.4M | $688.1M | $531.7M | $365.65M | $358.93M | $355.74M | $427.96M | $462.06M | $380.29M | |
| $21.2M | $48.6M | $30.2M | $218.8M | $131.1M | $0 | $0 | $1.5M | $12M | $900K | $33.1M | $93.4M | $0 | $0 | $2.23M | $19.03M | $75.15M | — | — | — | |
| $8.31B | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.4B | $7.34B | $7.56B | $6.93B | $6.3B | $5.87B | $5.75B | $4.44B | $3.71B | $3.32B | $3.47B | $3.08B | $2.88B | $2.39B | |
| $2.48B | — | — | — | — | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | $2.52B | $1.86B | $1.72B | $1.25B | $1.3B | $1.21B | $779.77M | |
| — | — | — | — | — | 25.87% | 33.84% | 48.98% | 43.77% | 43.55% | 45% | 45.44% | 40.94% | 36.29% | 33.64% | 34.16% | 26.48% | 29.59% | 29.62% | 24.59% | |
| $3.01B | — | — | — | — | $3.33B | $5.01B | $7.51B | $6.54B | $6.43B | $5.83B | $5.49B | $4.66B | $3.05B | $2.22B | $2.08B | $1.6B | $1.72B | $1.68B | $1.16B | |
| $275.1M | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M | $222.5M | $187.4M | $200.6M | $250.8M | $260M | $95.5M | $29.5M | $31.9M | $36.5M | $33M | $36.1M | $35.8M | $52M | — | |
| $139M | $125M | $67.6M | $276.5M | $89.3M | $11M | $42M | $120M | $112.5M | $78.5M | $63.4M | $22.1M | $12.2M | $8.2M | $29.5M | $19.2M | $22.3M | $48.5M | $72.1M | — | |
| -$309.2M | -$305.6M | -$343.6M | -$315.5M | $108.2M | -$1.1B | $497.4M | $83.3M | $11M | -$217M | -$218.7M | -$123.7M | -$25.8M | -$34.9M | -$744K | -$13.48M | -$18.98M | $37.25M | -$57.73M | $72.4M | |
| — | — | $0 | $0 | $2.6M | $34.9M | $3.3M | -$77.4M | $0 | $0 | $0 | -$12.5M | -$15.1M | -$17.2M | -$4.52M | $0 | $0 | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $15.06M | $16.32M | $23.97M | -$1.08M | -$16.73M | |
| $1.62B | $1.56B | $1.91B | $1.3B | $3.59B | $1.75B | $5.05B | $7.13B | $5.9B | $5.13B | $4.93B | $4.77B | $3.95B | $2.48B | $1.86B | $1.71B | $1.23B | $1.33B | $1.16B | $852.17M | |
| $251.1M | $263.6M | $273.8M | $135.3M | $632.8M | $52.5M | $992.3M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $989.9M | $601M | $470.55M | $444.53M | $331.33M | $355.62M | $365.78M | $272.42M | |
| $1.37B | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4B | $5.89B | $4.43B | $2.54B | $3.7B | $3.55B | $2.93B | $1.86B | $1.38B | $1.23B | $1.01B | $970.13M | $783.17M | $638.17M | |
| — | 13.07% | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | 30.25% | 26.86% | 25.02% | 24.45% | 21.31% | 22.16% | 19.11% | 20.12% | |
| — | $0 | $0 | $400K | -$85.3M | $171.5M | $59.9M | $0 | $43.3M | $131M | -$7.1M | $46.2M | $6.8M | $0 | $0 | $32.26M | -$106.7M | $6.93M | $6.94M | -$58.43M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $1.86B | $1.38B | $1.23B | $1B | $968.4M | $781.9M | — | |
| $1.41B | $1.25B | $1.65B | $1.17B | $2.99B | $1.75B | $3.84B | $5.99B | $4.51B | $2.54B | $3.61B | $3.38B | $2.9B | $1.89B | $1.35B | $1.23B | $933.17M | — | — | — | |
| USD/shares | $9.35 | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | $7.86 | $5.80 | $5.09 | $3.98 | $3.37 | $2.67 | $2.02 |
| USD/shares | $9.30 | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | $3.35 | $2.65 | $1.99 |
| shares | — | 146.5M | 145.6M | 144.7M | 145.3M | 149.1M | 160.9M | 187.1M | 204.9M | 212.6M | 218.4M | 230.7M | 236.4M | 236.9M | 237.94M | 242.4M | 252.31M | 287.36M | 292.33M | 315.84M |
| shares | — | 147.1M | 145.9M | 145.6M | 146M | 149.6M | 161.3M | 187.4M | 205.3M | 213M | 218.8M | 231.2M | 237.2M | 238.3M | 239.74M | 245.03M | 254.87M | 289.48M | 294.98M | 320.17M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2024: $36.14B in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 46 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.60×
Peer median 5.17×
EV/EBIT
—
P/E (TTM)
—
Peer median 22.58×
Peer medians compare against the 5 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $9,890,600,000 | $9,675,900,000 | $9,835,600,000 | $10,173,400,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $12,051,200,000 | $10,982,400,000 | $13,154,400,000 | $16,273,700,000 | $17,542,900,000 | $23,559,000,000 | $25,317,700,000 | $25,161,100,000 |
| Non Us | $11,679,100,000 | $13,221,200,000 | $13,572,300,000 | $15,129,800,000 | $16,979,400,000 | $14,867,200,000 | $13,945,400,000 | $12,387,300,000 |
| Europe Excluding Germany | — | — | $2,139,500,000 | $2,424,900,000 | $2,645,400,000 | $2,503,400,000 | $2,678,000,000 | — |
| Segment Geographical Groups Of Countries Group Other | — | — | $531,200,000 | $646,900,000 | $688,400,000 | $619,300,000 | $629,500,000 | $511,400,000 |
| Germany | — | — | $868,000,000 | $926,200,000 | $1,162,400,000 | $1,161,200,000 | $1,126,400,000 | — |
| Asia | — | — | $863,400,000 | $767,300,000 | $761,400,000 | $629,600,000 | $432,500,000 | $377,400,000 |
| Europe | — | — | — | — | — | $3,664,600,000 | $3,804,400,000 | $3,403,200,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $7,119,400,000 | $7,213,500,000 | $7,246,700,000 | $7,987,800,000 | $8,846,900,000 | $10,692,200,000 | $11,379,800,000 | $10,886,800,000 |
| MS Product Revenues | $4,038,900,000 | $4,349,800,000 | $4,661,900,000 | $5,430,200,000 | $6,096,700,000 | $7,832,100,000 | $8,529,300,000 | $8,595,200,000 |
| Rare Disease Product Revenue | $2,154,200,000 | $1,988,100,000 | $1,803,000,000 | $1,793,500,000 | $1,905,100,000 | — | — | — |
| Revenues from Anti-CD20 Therapeutic Programs | $1,860,600,000 | $1,749,900,000 | $1,689,600,000 | $1,700,500,000 | $1,658,500,000 | $1,977,800,000 | $2,290,400,000 | $1,980,200,000 |
| Tysabri Product | $1,665,400,000 | $1,715,000,000 | $1,876,900,000 | $2,030,900,000 | $2,063,100,000 | $1,946,100,000 | $1,892,200,000 | $1,864,000,000 |
| SPINRAZA | $1,546,800,000 | $1,573,200,000 | $1,741,200,000 | $1,793,500,000 | $1,905,100,000 | $2,052,100,000 | $2,097,000,000 | $1,724,200,000 |
| Fumarate | $1,426,500,000 | $1,595,100,000 | $1,588,800,000 | $1,997,300,000 | $2,362,300,000 | $3,905,400,000 | $4,438,200,000 | $4,274,100,000 |
| Royalty Attributed to OCREVUS | $1,414,900,000 | $1,339,500,000 | $1,266,200,000 | $1,136,300,000 | $991,700,000 | $845,400,000 | — | — |
| Interferon | $945,600,000 | $968,000,000 | $1,105,700,000 | $1,305,400,000 | $1,566,100,000 | $1,877,500,000 | $2,101,800,000 | $2,363,000,000 |
| VUMERITY | $746,800,000 | $628,000,000 | $576,300,000 | $553,400,000 | $410,400,000 | $64,300,000 | $5,500,000 | $0 |
| Contract Manufacturing Royalty and Other Revenue | $732,900,000 | $652,600,000 | $899,300,000 | $485,100,000 | $476,300,000 | — | — | — |
| Biosimilars | $729,100,000 | $793,100,000 | $770,000,000 | $751,100,000 | $831,100,000 | $795,800,000 | $738,300,000 | $545,100,000 |
| AVONEX | $695,500,000 | $707,500,000 | $811,000,000 | $973,500,000 | $1,208,700,000 | $1,491,900,000 | — | — |
| TECFIDERA | $679,700,000 | $967,100,000 | $1,012,500,000 | $1,443,900,000 | $1,951,900,000 | $3,841,100,000 | $4,432,700,000 | $4,274,100,000 |
| Contract Manufacturing and Other Revenue | $679,400,000 | $592,100,000 | $848,200,000 | $417,700,000 | $427,700,000 | $719,100,000 | — | — |
| SKYCLARYS | $520,500,000 | $382,500,000 | $55,900,000 | $0 | $0 | — | — | — |
| BENEPALI | $453,200,000 | $479,100,000 | $438,800,000 | $441,000,000 | $498,300,000 | $481,600,000 | $486,200,000 | $485,200,000 |
| PLEGRIDY | $250,100,000 | $260,500,000 | $294,700,000 | $331,900,000 | $357,400,000 | $385,600,000 | — | — |
| Other | $197,200,000 | $82,500,000 | $11,800,000 | $13,000,000 | $14,000,000 | — | — | — |
| ZURZUVAE | $195,100,000 | $72,200,000 | $1,600,000 | $0 | — | — | — | — |
| IMRALDI | $190,200,000 | $213,100,000 | $222,100,000 | $224,500,000 | $233,400,000 | $216,300,000 | $184,000,000 | $16,700,000 |
| Alzheimers Collaboration | $177,700,000 | $59,900,000 | $0 | $0 | — | — | — | — |
| QALSODY | $86,900,000 | $32,400,000 | $5,900,000 | $0 | $0 | — | — | — |
| Royalty | $53,500,000 | $60,500,000 | $51,100,000 | $67,400,000 | $48,600,000 | $55,500,000 | $17,000,000 | $38,700,000 |
| FLIXABI | $52,600,000 | $63,200,000 | $77,400,000 | $81,300,000 | $99,400,000 | $97,900,000 | $68,100,000 | $43,200,000 |
| BYOOVIZ | $32,400,000 | $36,600,000 | $31,700,000 | $4,300,000 | $0 | $0 | — | — |
| FUMADERM and ADUHELM | $2,100,000 | $10,300,000 | $10,200,000 | $13,000,000 | — | — | — | — |
| FAMPYRA | $1,400,000 | $71,700,000 | $90,500,000 | $96,600,000 | $105,200,000 | $103,100,000 | $97,100,000 | $92,700,000 |
| TOFIDENCE | $700,000 | $1,100,000 | $0 | $0 | — | — | — | — |
| ADUHELM | — | — | — | $4,800,000 | $3,000,000 | $0 | $0 | — |
| ALPROLIX | — | — | — | — | — | — | $0 | $0 |
| ELOCTATE | — | — | — | — | — | — | $0 | $0 |
| FUMADERM | — | — | — | $8,200,000 | $11,000,000 | $12,200,000 | $15,200,000 | $22,300,000 |
| Hemophilia Products | — | — | — | — | — | — | $0 | $0 |
| Other Corporate Revenues | — | — | — | — | $427,700,000 | $719,100,000 | $584,500,000 | $459,400,000 |
| ZINBRYTA | — | — | — | — | — | $0 | $0 | $1,400,000 |
| Product And Service Other | — | — | — | $485,100,000 | $476,300,000 | $774,600,000 | $707,700,000 | $585,900,000 |
Key facts
CIK
875045
CUSIP
09062X103
13F (30d)
611 filings
599 filers
Visit website
Investor relations